应用~99m锝标记抗癌胚抗原单克隆抗体行卵巢肿瘤放射免疫显像的研究

Radioimmunoimaging assay of ovarian tumorwith ￣(99m)Tc labeled anti-CEA monoclonalantibody

应用放射性核素锝（￣（９９ｍ）Ｔｃ）标记抗癌胚抗原（ＣＥＡ）单克隆抗体（ＭｃＡｂ）放射免疫显像（ＲＩＩ），对１３例卵巢恶性肿瘤、４例卵巢癌手术、化疗后无复发的病人以及１３例卵巢及盆腔内其他良性病变的病人，在注射标记抗体后第１８、２４小时进行盆腹腔前后位平面显像观察。结果：卵巢恶性肿瘤ＲＩＩ的阳性检出率为１００％（１３／１３），卵巢癌手术、化疗后无复发和卵巢及其他良性病变的阴性预测率为９４％（１６／１７），肿瘤转移灶的检出率为６３％（１０／１６）。提示：￣（９９ｍ）Ｔｃ－ＣＥＡ－ＭｃＡｂ的ＲＩＩ对卵巢恶性肿瘤的定性、早期诊断有一定意义。

adioimmunoimaging (RI I) assay with ￣(99m)Tc la-beled anti-CEA monoclonal antibody was performedin 31 patients with suspected primary or reccurrentmaligment ovarian tumor. The radiation dose ragingirom 920MBq to 110MBq(1mgIgG) was administeredi.v for each patient. Anterior-posterior views of thepelvis and abdomen were obtained routinely withycamera dunng 18～24 hour after the application ofantibody. The results of RII were compared with thefindings in operation or CT examination. Sensitivity indiagnosis was 100%(13 /13), specificity was94%(16 /17) and metastatic foci sensitivity was63 %(10/16). The serum CA_(125) in this study appearedto be correlated with the results of RII. However. in 2patients with nomial serum CA_(125) titers RII revealedtrue positive.The preliminary clinical results of RII with￣(99m)Tc-MAb showed that RII is a promising methodfor the detection of malignant ovarian tumors.